Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : EuCorVac-19
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Korea Institute of Science and Technology
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Eubiologics is developing EuCorVac-19, its vaccine platform, which consists of owned antigen, EulMT in-licensed from Korea Institute of Science and Technology and SNAP technology of POP Biotechnologies that EuBiologics has invested.
Product Name : EuCorVac-19
Product Type : Vaccine
Upfront Cash : Inapplicable
March 02, 2022
Lead Product(s) : EuCorVac-19
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Korea Institute of Science and Technology
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : EuCorVac-19
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
EuBiologics Gets an IND Approval for Phase I/II Clinical Trial of 'EuCorVac-19' in Korea
Details : The EuCorVac-19 under development is a safe vaccine formulated with the coronavirus spike protein using recombinant protein technology and with a potent adjuvant.
Product Name : EuCorVac-19
Product Type : Vaccine
Upfront Cash : Inapplicable
January 21, 2021
Lead Product(s) : EuCorVac-19
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable